CHEK2 and breast cancer: Individuals carrying heterozygous pathogenic variants in ATM present a 33% cumulative lifetime risk for BC by 80 years of age [7], whereas certain variants in the CHEK2 gene are associated with increased BC risk, with a cumulative lifetime risk ranging from 28% to 37% depending on family history [8,9].